Dr Stuart Bond receives IPA award for infection prevention work

Dr Stuart Bond, Consultant Antimicrobial Pharmacist and Director of Innovation at Mid Yorkshire Teaching NHS Trust, has won an award for his groundbreaking infection prevention work for patients undergoing joint replacement surgery.

Dr Bond’s team introduced antimicrobial photodynamic therapy (aPDT) into the NHS. They managed to reduce surgical site infections by 71 percent for knee and hip replacements at the Trust, which has greatly improved patient outcomes and has also reduced costs.

This work has now been recognised by the International Photodynamic Association (IPA), who presented Dr Bond with the President’s Award at the 19th World Congress of the IPA, held in Shanghai, China.

Dr Bond said: “It’s an honour and a privilege to receive the President’s Award from the IPA. I would also like to recognise the team at Pontefract Elective Orthopaedic Suite, who did the patient-facing work and administered the treatments. Without their teamwork, this award would not have been possible.”

Dr Colin Hopper, President of the IPA, said: “Dr Bond and his team at Mid Yorkshire were the first to operationalise aPDT within the NHS. Their published findings have not only demonstrated the clinical value of aPDT (photodisinfection) but have also set a benchmark in infection prevention.

“Their leadership underscores the clinical importance of aPDT in an era of rising multidrug resistance and positions the NHS as a global innovator in antibiotic stewardship, health, and patient safety.”

Dr Bond has served as a Consultant Antimicrobial Pharmacist since 2017 and holds a PhD in educational strategies to improve antimicrobial stewardship.

As a Visiting Fellow at the University of Huddersfield, Dr Bond contributes to PhD supervision and teaches pharmacy and non-medical prescribing students at both Huddersfield and the University of Leeds.

Under Dr Bond’s leadership The Mid Yorkshire Teaching NHS Trust Innovation Group has played a pivotal role in evaluating and adopting clinically validated, cost-effective technologies like aPDT.

Their efforts continue to strengthen the Trust’s standing as a leading centre for innovation in healthcare delivery and antimicrobial stewardship.